BiondVax Pharmaceuticals (NASDAQ:BVXV) Research Coverage Started at StockNews.com

Posted by on Jun 20th, 2023

Investment analysts at StockNews.com started coverage on shares of BiondVax Pharmaceuticals (NASDAQ:BVXV – Get Rating) in a report issued on Tuesday. The brokerage set a “hold” rating on the stock.

BiondVax Pharmaceuticals Trading Up 5.0 %

Shares of BVXV stock opened at $1.46 on Tuesday. The stock has a market capitalization of $2.73 million, a PE ratio of -0.41 and a beta of 2.47. BiondVax Pharmaceuticals has a 1-year low of $1.29 and a 1-year high of $13.50. The business has a 50-day moving average of $1.77 and a 200 day moving average of $2.80. The company has a debt-to-equity ratio of 5.92, a current ratio of 4.28 and a quick ratio of 4.28.

BiondVax Pharmaceuticals (NASDAQ:BVXV – Get Rating) last issued its earnings results on Monday, April 17th. The company reported ($0.30) earnings per share for the quarter. As a group, sell-side analysts anticipate that BiondVax Pharmaceuticals will post -0.01 earnings per share for the current year.

Institutional Investors Weigh In On BiondVax Pharmaceuticals

An institutional investor recently raised its position in BiondVax Pharmaceuticals stock. Sabby Management LLC increased its position in BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV – Get Rating) by 47.8% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 325,974 shares of the company’s stock after purchasing an additional 105,412 shares during the quarter. BiondVax Pharmaceuticals makes up about 0.6% of Sabby Management LLC’s investment portfolio, making the stock its 11th largest holding. Sabby Management LLC owned about 17.45% of BiondVax Pharmaceuticals worth $704,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 20.88% of the company’s stock.

BiondVax Pharmaceuticals Company Profile

(Get Rating)

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.

Further Reading

Receive News & Ratings for BiondVax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiondVax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.